N -- Full year net sales for continuing operations1 up 9% (cc2, +6% USD): -- Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc...
N -- Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): -- Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von...
N -- Hausse du chiffre d'affaires net des activités poursuivies1 de 9% sur l'exercice entier (tcc2, +6% USD): -- Pharmaceuticals: cette unité opérationnelle progresse de...
N Basel, January 6, 2020 -- Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned...
N -- Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication -- Fevipiprant was well tolerated with adverse events balanced across...
N Basel, December 5, 2019 -- Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation...
N -- Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve...
N -- Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 -- Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to...
N -- Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira(R)*[1]...
N -- FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study -- Adverse events that might be expected from the...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 76.79 | 76.79 | 76.79 | 419 | 76.79 | DE |
4 | 0 | 0 | 76.79 | 76.79 | 76.79 | 10576 | 76.79 | DE |
12 | 0 | 0 | 76.79 | 76.79 | 76.79 | 4719 | 76.79 | DE |
26 | 0 | 0 | 76.79 | 76.79 | 76.79 | 3371 | 76.79 | DE |
52 | 0 | 0 | 76.79 | 76.79 | 76.79 | 9601 | 76.79 | DE |
156 | 0 | 0 | 76.79 | 76.79 | 76.79 | 21445 | 76.79 | DE |
260 | 0 | 0 | 76.79 | 76.79 | 76.79 | 17887 | 76.79 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales